^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG CLASS:

Cytochrome P450 inhibitor

11d
Co-encapsulated fluorescent magnetic nanoparticles for potential applications in breast cancer therapy: Exploratory in vitro and in vivo studies. (PubMed, Int J Pharm)
This study describes, for the first time in literature, a suitable approach to develop co-encapsulated magnetic nanoparticles based on fluorescent biotinylated N-palmitoyl chitosan, hydrophobic magnetite, Docetaxel and Verapamil. No significant toxicity was observed for magnetic nanoparticles in the rats. Overall, these findings suggest that the developed magnetic nanoplatforms represents a promising candidate for breast cancer applications and merits further in vivo investigation needed to elucidate the action mechanism of encapsulated therapeutics and their pharmacologic activity.
Preclinical • Journal
|
CXCL8 (Chemokine (C-X-C motif) ligand 8)
|
docetaxel
14d
Simultaneous Determination of Venetoclax and Posaconazole in Human Plasma by UPLC-MS/MS: Application to Therapeutic Drug Monitoring in Acute Myeloid Leukemia Patients. (PubMed, Drug Des Devel Ther)
The trough concentrations of venetoclax were 9326.88 ± 12,169.05 ng/mL in patients treated with venetoclax alone, and 31,623.55 ± 28,453.67 ng/mL in patients treated with venetoclax in combination with posaconazole. A rapid and simple method was established and successfully applied to the simultaneous determination of the concentrations of venetoclax and posaconazole in AML patients, providing a basis for TDM and clinical pharmacokinetic analysis of these drugs in AML patients.
Journal
|
CYP3A4 (Cytochrome P450, family 3, subfamily A, polypeptide 4)
|
Venclexta (venetoclax) • Noxafil (posaconazole)
28d
KF2025#1 Trial: Ketamine, Cannabidiol and Cobicistat Interaction Study (clinicaltrials.gov)
P1, N=12, Not yet recruiting, Helsinki University Central Hospital
New P1 trial
|
Tybost (cobicistat) • Epidiolex (cannabidiol)
1m
New trial
1m
DRG Explant Model for Understanding Mechanism of Oxaliplatin-Induced Peripheral Neuropathy and Identifying Potential Therapeutic Targets. (PubMed, Antioxidants (Basel))
Oxaliplatin-triggered chemotherapy-induced peripheral neuropathy (CIPN) is a common and debilitating side effect of cancer treatment that limits the efficacy of chemotherapy and negatively impacts patients' quality of life dramatically. Notably, inhibition of TXNIP with verapamil reduced oxidative stress levels. Our results demonstrated the use of DRG explants as an efficient model to study the mechanisms of CIPN and screen for potential treatments.
Journal
|
TXNIP (Thioredoxin Interacting Protein)
|
oxaliplatin
1m
Enrollment change
|
Keytruda (pembrolizumab) • carboplatin • doxorubicin hydrochloride • AiRuiKa (camrelizumab) • albumin-bound paclitaxel • cyclophosphamide • epirubicin • Noxafil (posaconazole)
2ms
Potency-enhancing mutations in E3-19K and i-leader increase the cytolytic activity of the PH20/SPAM1-armed oncolytic adenovirus Ad5Δ24RGD. (PubMed, Mol Ther Oncol)
In some cell lines, the fiber modification F5RGD10(2C) or verapamil treatment further improves actual spread efficiency. Nelfinavir inhibits spread and plaque formation of oncolytic adenoviruses with the 19KSS-iLQ125Ter modifications, irrespective of adenovirus death protein (ADP) expression...We identified an insertion site downstream of the L3-23K region that supports relatively high hPH20 activity while preserving the enhanced oncolytic potency of the virus. Combining 19KSS-iLQ125Ter with hPH20 expression may potentially improve therapeutic benefit in glioma.
Journal
|
SPAM1 (Sperm Adhesion Molecule 1)
|
Viracept (nelfinavir)
2ms
Posaconazole attenuates arsenic trioxide toxicity and enhances safety and efficacy while reducing invasion and metastasis in non-small-cell lung cancer. (PubMed, Pulm Pharmacol Ther)
Furthermore, flow cytometry and colony formation assays revealed that PCZ attenuates and reduces the apoptotic/necrotic effects of ATO. In conclusion, PCZ synergistically and effectively reduces the adverse cytotoxic effects of ATO in lung cancer cells, providing a promising new therapeutic strategy for lung cancer treatment.
Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • GLI1 (GLI Family Zinc Finger 1) • HMGA2 (High mobility group AT-hook 2) • MMP9 (Matrix metallopeptidase 9)
|
arsenic trioxide • Noxafil (posaconazole)
2ms
Posaconazole for Pulmonary Fungal Infection Prophylaxis in Hematopoietic Stem Cell Transplantation Patients (clinicaltrials.gov)
P=N/A, N=360, Completed, Institute of Hematology & Blood Diseases Hospital, China | Not yet recruiting --> Completed
Trial completion
|
Noxafil (posaconazole)
2ms
New trial
|
Noxafil (posaconazole)